Introduction
High-throughput technology has provided an unbiased global view of biological processes. This strategy, applied to the analysis of tumor tissue, defined immune characteristics that are associated with the natural or treatment-induced evolution of cancer. Although epidemiological and observational studies in humans have shown that chronic inflammation promotes tumorigenesis (Trinchieri, 2012) , when patients bearing established tumors are prospectively followed, the role of a polarized immunity process counteracting tumor growth and progression emerges.
Observational studies linked to clinical-outcome analysis suggest the existence and relevance in humans of the immunosurveillance phenomenon, characterized earlier by Schreiber and colleagues through elegant studies in animals (Shankaran et al., 2001 ). According to the immunoediting theory, the host can control tumor growth through the activation of adaptive and innate immune mechanisms, driven by the activation of interferon-g (IFN-g)-dependent pathways (Schreiber et al., 2011) . This process can also lead to the selection of tumor cells capable of escaping the immune pressure, which explains the paradoxical observation of tumor development in immunecompetent individuals (Schreiber et al., 2011) . However, a convincing number of observations have demonstrated that the presence and maintenance of an inflammatory status in or by established tumors is associated with a more favorable prognosis and/or treatment responsiveness.
Redundant signatures are observed among cancers with a better prognostic connotation (prognostic signatures), cancers with an increased likelihood to respond to therapy (predictive signatures), or cancers studied during treatments that subsequently underwent complete regression (mechanistic signatures). Moreover, similar pathways are shared by other phenomena in which tissue-specific immune destruction occurs, such as autoimmune diseases, allograft rejection, graft-versushost disease (GVHD), and acute infection resulting in clearance of pathogen-infected cells.
Here, we will focus on dominant themes shared by the aforementioned conditions related to positive outcomes in cancer, whereas other salient characteristics of the tumor microenvironment that may otherwise affect the behaviors of tumors predominantly toward negative outcomes are not included in this review (e.g., see Motz and Coukos, 2013 in this issue) . Three concepts will be defined, compared, and discussed here: the immune contexture, the Immunoscore, and the immunologic constant of rejection (ICR) (Figures 1 and 2 ).
Historical Perspective
Contrary to those who view the field as nothing more than wishful thinking, cancer immunology has made many major discoveries and established a strong foundation over the last century. From its origins, the field has been plagued by difficulties. Firstly, cancer immunology is a hybrid discipline. Secondly, the cancer field was previously led predominantly by geneticists, oncologists, pathologists, and other medical specialists. However, as early as the 1890s, William B. Coley observed that some cancer patients experienced spontaneous remission of their tumors when they contracted acute infections (Coley, 1893) . Coley went on to develop a relatively safe and effective mixture of bacterial products (Coley's toxins) for treating cancer patients. This work was overshadowed, however, by the advent of X-ray and radium treatment and, subsequently, chemotherapy. The field of immunology during these first visionary years remained neglected. During the mid-20 th century, Richmond Prehn and
Joan Main demonstrated immune rejection of transplanted syngeneic chemically-induced tumors (Prehn and Main, 1957) . A few years later, based on increasing observations in mouse models, Lewis Thomas and McFarlane Burnet proposed a theory of ''immune surveillance of cancer,'' speculating that the immune system might be capable of destroying nascent malignancies (Burnet, 1970; Thomas, 1982) . The concept of cancer immune surveillance became moribund following the finding that athymic nude mice did not have increased susceptibility to tumors induced by methylcholanthrene (Stutman, 1974 (Stutman, , 1975 . However, we now know that nude mice have high levels of natural killer (NK) cells and other innate immune cells (Dunn et al., 2004 ). Regardless of these major discoveries, the cancer immunology field became increasingly controversial, and the scientific validity of Coley's diagnosis was questioned. This pessimistic view of cancer immunity was gradually rebutted by many novel experimental observations, such as the discovery of the tumor necrosis factor (Carswell et al., 1975) and the demonstration of the rejection of poorly immunogenic spontaneous tumors after immunization with mutagenized tumors (Van Pel et al., 1983) . In 1991, the field entered the molecular era of immunology with the identification of antigen structures and the sequences of genes encoding tumor antigens that are recognized by T cells (van der Bruggen et al., 1991) . This discovery generated a wave of optimism and hope for vaccination and immune-modulatory approaches against cancer. In 1995 and 1998, two inflammatory cytokines, IFN-a and interleukin-2 (IL-2), were approved for the treatment of melanoma (adjuvant and metastatic settings, respectively). However, immonotherapies developed in these years had limited survival benefit restricted to a minor group of patients, again plunging the field into question.
The renaissance of tumor immunology really began a decade ago, spurred by three major achievements. First, there was the demonstration of immunosurveillance (integrated in the immunoediting theory) using gene-deletion mouse models (Shankaran et al., 2001 ) and the demonstration of the equilibrium phase of cancer (Koebel et al., 2007) . Second, there was the demonstration of the importance of the patients' tumor immune reaction for their survival. Adaptive immune cell infiltration was shown to have a prognostic value superior to the classical extension and invasion tumor criteria (Galon et al., 2006 (Galon et al., , 2007 . Moreover, an active-tumor microenvironment conducive to immune recognition was shown to be predictive of response to immunotherapy . Third, the remarkable successes of several immunotherapies generated tremendous enthusiasm among oncologists and immunologists. In the last five years, several types of immunotherapies have been shown to have great clinical impact. These include adoptive T cell transfer therapy (Kalos and June, 2013; Restifo et al., 2012) ; vaccines such as the first cellular vaccine approved by the United States Food and Drug Administration (FDA), Sipuleucel-T (Kantoff et al., 2010) ; and the gp100 vaccine in combination with IL-2 (Schwartzentruber et al., 2011) . Additionally, checkpoint blockade inhibitors, such as the FDA-approved anti-CTLA4 monoclonal antibody (mAb) (ipilimumab) (Hodi et al., 2010; Robert et al., 2011) and the anti-PD-1:PD-1 ligand mAbs Topalian et al., 2012) , have recently revolutionized the field (Chen and Mellman, 2013) . The area of cancer immunology remains an ever-increasing multidisciplinary field, thriving from the input of immunologists and clinicians alike who work in concert to save the lives of cancer patients.
Prognostic Immune Signatures in Distinct Types of Cancer
Prognostic markers are clinical measures used to evaluate individual patient outcome, such as recurrence of disease or death, independent of therapy. These prognostic factors range from simple measures, such as the stage of disease based on tumor invasion, to progressively more comprehensive indicators encompassing the biological complexity of the disease Galon et al., 2007) . Indeed, the evolution of cancer is greatly influenced by the complex milieu in which it develops, + , and CD45RO + T cells and their location at the tumor center and invasive margin combined with the quality of tertiary LIs. Numerous analyses of large patient cohorts confirmed an association between these patterns and favorable disease outcome. The Immunoscore is derived from three aspects of the immune contexture: the type, density, and location of immune cells. The functional orientation of the immune contexture is characterized by immune signatures qualitatively similar to those predicting response to immunotherapy, which are observable in association with the broader phenomenon of immune-mediated, tissue-specific destruction. These signatures are detectable during regression of cancer following immunotherapy, allograft rejection, GVHD, flares of autoimmunity, or destruction of virally infected cells to clear intracellular pathogens. We defined them as the immunologic constant of rejection (ICR). Genes underlying Th1 polarization, related chemokines (CXCR3 and CCR5 ligands), and genes associated with the activation of cytotoxic mechanisms more frequently described in association with the broader phenomenon of immune-mediated, tissue-specific destruction (ICR genes) are in bold.
accommodating intricate tumor-cell interactions within the host microenvironment including a vast catalog of cells, vessels, cytokines, and chemokines. Histological analysis of human tumors has highlighted the importance of tumor immune infiltrates including macrophages, dendritic cells (DCs), polymorphonucleate cells, NK cells, B cells, and T cells, revealing a broad patient-to-patient diversity (Mlecnik et al., 2011a; Senovilla et al., 2012) . Among an increasing variety of investigations supporting the relevance of the differential presence of components of the immune system in determining the evolution of cancer (Jochems and Schlom, 2011) , a predominant theme based collectively on direct human observations suggests that high densities of tumor-infiltrating lymphocytes correlate with improved clinical outcome (Mlecnik et al., 2011a) . The correlation between a robust lymphocyte infiltration and patient survival has been well documented in melanoma, ovarian, head and neck, breast, urothelial, colorectal, lung, hepatocellular, gallbladder, and esophageal cancer (reviewed in Angell and Galon, 2013; Fridman et al., 2012) . The majority of studies observed that high densities of CD3 + T cells, CD8 + cytotoxic T lymphocytes (CTLs), and CD45RO + memory T cells are associated with a longer disease-free survival (DFS) and/or improved overall survival (OS). Thus, the role of the adaptive immune response in controlling tumor progression is becoming increasingly appreciated. These prognostic immune parameters have been comprehensively described in colorectal cancer (CRC) as the immune contexture, which is defined as the type, density, functional orientation, and location of adaptive immune cells within distinct tumor regions Galon et al., 2006 Galon et al., , 2007 (Figure 1 ). Chemoattraction and adhesion were shown to play critical roles in determining the density of intratumoral immune cells. Expression of these specific chemokine signatures correlated with differing densities and spatial localization of T cell subpopulations within tumor regions and with specific T cell receptor (TCR) repertoires, predicting patient survival . High expression levels of these immune-related genes were associated with prolonged DFS in patients with CRC, and long-term OS correlated with these immune gene signatures .
Gene signatures characterized by the activation of immunerelated genes such as chemokines (CXCL9 and CXCL10), cytotoxic granules (GZMA and GZMB), T cell markers (CD8A), human leukocyte antigen (HLA) molecules and other IFN-stimulated genes (STAT1 and GBP1) , and NK-related genes were observed in tumors from patients with early-stage breast cancer who enjoyed prolonged DFS. Interestingly, and in line with this observation, analysis of a large cohort of breast cancer samples identified a specific cluster of good-prognosis tumors characterized by a low number of somatic copy-number aberrations and by the upregulation of congruent immune genes (e.g., CD3D, CD8A, CCL5, CXCL9, CXCL10, CXCR3, STAT1, and other IFN-stimulated genes) (Curtis et al., 2012) . Similar associations were also observed in additional colorectal, lung, hepatocellular, ovarian, melanoma, and breast cancer studies Chew et al., 2012; Curtis et al., 2012; Desmedt et al., 2008; Galon et al., 2006; Jiang et al., 2010; Leffers et al., 2010; Mann et al., 2013; Messina et al., 2012; Mlecnik et al., 2010; Moran et al., 2002; Pagè s et al., 2005; Tosolini et al., 2011; Verhaak et al., 2013; Zhang et al., 2003 ) (Table 1). Table 1 summarizes gene-signature data, but does not include additional valuable research from other approaches, such as flow cytometry and immunohistochemistry. Notably, as discussed later, a large proportion of the activation signatures associated with good prognosis are observed in other conditions related to immune-mediated, tissue-specific destruction and are therefore included in the concept of the ICR.
Traditionally, tumor-invasion parameters such as the anatomic extent of the tumor burden (T), the presence of cancer cells in draining lymph nodes (N), and evidence of distant metastases (M) have been combined to provide the American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) TNM classification, serving as the prominent prognostic stratification system. This classification has proved valuable in estimating the outcome of patients for a variety of cancers (Wittekind et al., 2002) . However, it is recognized that clinical outcome can vary significantly among patients within the same histological stage (Nagtegaal et al., 2012) . Data collected from large cohorts of human CRCs have demonstrated the impact of an immune-based classification strategy, utilizing a simple test derived from the immune contexture that has been termed the Immunoscore (Figures 1 and 2 
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The abbreviations used are as follows: Th1, T helper cell type 1; STAT, signal transducers and activator of transcription; IFN-g-SG, interferon-g-stimulated genes; IRF, IFN-regulatory factor; chemo, chemotherapy; IL-2, interleukin-2.
incrementally from Immunoscore 0 (I0), which has low densities of both cell types in both regions, to Immunoscore 4 (I4), which has high densities of both cell populations in both regions. The prognostic value of using these criteria was demonstrated in patients with early-stage CRC (TNM stages I and II) for predicting survival and relapse (Pagè s et al., 2009) , wherein the five Immunoscore groups were associated with highly significant changes in DFS and OS (p < 0.0001). Patients with I4 survived for a long time; 95% of the I4 patients had no tumor recurrence for 18 years, whereas 50% of I0 patients had tumor recurrence within 2 years. The prognostic value was then demonstrated in patients at all cancer stages (TNM stages I-IV) (Mlecnik et al., 2011b) . More importantly, for the first time, combined evidence illustrates the dependency of TNM staging stratification on factors of the immune response (Galon et al., 2006; Mlecnik et al., 2011b) . Indeed, Cox multivariate analysis shows that tumor progression (T stage) and invasion (N stage) are statistically dependent on the Immunoscore. The Immunoscore remained the only significant criterion over TNM staging for DFS or OS, illustrating that it may have a prognostic value superior to the TNM classification (Broussard and Disis, 2011; Galon et al., 2006; Mlecnik et al., 2011b) . Thus, lymphocyte infiltration associated with a Th1 cell polarization of the adaptive immune response bears a significant impact on the natural history of cancer patients.
Predictive Immune Signatures in Distinct Types of Cancer
Prognostic markers are useful for assessing the risk of an individual patient and providing helpful insights into cancer biology. However, they do not assist in treatment selection according to the likelihood of therapeutic effectiveness, a role that pertains to predictive biomarkers (Angell and Galon, 2013) . Numerous therapeutic regimes are currently used to treat cancer, including radiotherapy, chemotherapy, kinase inhibitors (e.g., BRAF and c-Kit inhibitors; Corless et al., 2011; Sharma et al., 2012) , and antibody therapy directed to proteins expressed by cancer cells (e.g., HER2, EGFR, and CD20; Galluzzi et al., 2012c) or to soluble factors favoring tumor growth through the perturbation of the tumor microenvironment (i.e., vascular endothelial growth factor; Terme et al., 2013) . In addition to the immunotherapies mentioned earlier, other immunotherapeutic approaches such as Toll-like receptor (TLR) agonist van den Boorn and Hartmann, 2013) , novel generation of DC-based vaccination (Palucka and Banchereau, 2013; Galluzzi et al., 2012a; Vacchelli et al., 2012c) , and engineered T cell transfer therapy (Kalos and June, 2013; Restifo et al., 2012) have been shown to induce significant antitumor activity. In most cases, responses were largely unpredictable and restricted to a limited portion of patients. Several in vitro and in vivo experiments, as well as a few clinical observations, suggest that not only immunotherapeutic approaches, but the majority of the aforementioned therapies (Frederick et al., 2013; Fridman et al., 2012; Galluzzi et al., 2012b; Ma et al., 2013) including radiotherapy (Formenti and Demaria, 2013) can trigger an immune-mediated antitumor response ( Figure 3A ). Among the hurdles related to the development of novel anticancer immunotherapies stands the absence of biomarkers predictive of immune responsiveness. Recent studies have begun to highlight the role that tumor cell death triggered by chemotherapy may play as an immune adjuvant contributing to treatment success Zitvogel et al., 2013, this issue) . Pari passu, investigations aimed at assessing the presence of a strong immune infiltrate and its functional or molecular orientation supported its role in predicting therapeutic response .
High-throughput gene-expression profiling unveiled dominant themes that are consistently linked to the effectiveness of distinct approaches (Bedognetti et al., 2010) . Notably, molecular pathways predictive of immune responsiveness largely overlap with those associated with favorable prognosis. A decade ago, gene-expression profile studies first suggested that metastatic melanoma lesions likely to respond to IL-2 and vaccination bear an inflammatory status characterized by the preactivation of cytotoxic mechanisms and the upregulation of IFN signaling . Moreover, real-time quantitative PCR (qPCR) measurement demonstrated similar expression of lymphoid cell markers (e.g., CD3D and CD8A) in pretreatment responding versus nonresponding lesions. This observation suggests that some tumors might display a functional active immunophenotype independently of the abundance of infiltrating immune cells . Furthermore, gene signatures including T cell markers and specific chemokines were associated with favorable prognosis in two metastaticmelanoma trials, evaluating the activity of multiple peptide vaccination plus IL-12 and DC-based vaccination (Gajewski et al., 2010; Gajewski et al., 2007, ASCO, abstract; Gajewski et al., 2009, ASCO, abstract) . More refined network and pathway analyses recently confirmed and better defined these early findings. In a prospective pilot study, Weiss et al. (2011) showed that pretreatment biopsies of lesions from patients with metastatic melanoma subsequently responding to the administration of IL-2 displayed a signature of immune activation, centered on IFN-g signaling. Ji et al. (2012) recently applied gene-expression profiling to the study of melanoma metastases from patients treated with anti-CTLA4 (ipilimumab). The top 26 genes upregulated in samples from responding patients include CD8A, HLA-DQA1, CCL4, and CCL5 (CCR5 ligands); CXCL9, CXCL10, and CXCL11 (CXCR3 ligands); and NKG7, GZMB, and PRF1 (immune effectors). In line with these findings, a coordinated upregulation of CCL5, CXCL9, CXCL10, and CXCL11 in pretreatment lesions was found to be predictive of responsiveness to adoptive-transfer therapy and IL-2 in the same disease setting (Bedognetti et al., 2012, ASCO, abstract) .
Notably, in the aforementioned ipilimumab trial (Ji et al., 2012) , the overexpression of IDO1 (a classical immunosuppressive gene) also correlates with treatment effectiveness. Concordantly, in the same setting, the pretreatment overexpression of FOXP3 (a marker of bona-fide T regulatory cells) and IDO proteins by immune infiltrates positively correlates with ipilimumab efficacy (Hamid et al., 2011) . Similarly, only tumors expressing PD-1 ligands seem to be sensitive to anti-PD1 therapy . Overall, the studies evaluating immune-checkpoint blockade molecules (i.e., anti-CTLA4 and anti-PD1/anti-PD1 ligand mAbs) have provided two important hypotheses. The first is that, in metastatic cancers, the immune system is not an inert system, but rather an actively suppressed one. The second hypothesis is that tumors responsive to treatment display an inflammatory status accompanied by the concomitant counteractivation of immune-suppressive mechanisms, probably reflecting ongoing immune-escape processes. This suppressed immune response could however be restored by the blockade of the immune checkpoint. Tumors lacking these two characteristics are insensitive to therapeutic immune manipulations. It is not known whether this deficiency depends on the intrinsic inability of some tumors to trigger the immune system ab initio or whether it is the result of an immunologic epilog in which immune-escape mechanisms have conclusively prevailed.
Robust data from two randomized phase II trials recently identified a signature predictive of responsiveness to MAGE-A3 vaccination (Ulloa-Montoya et al., 2013; Wang et al., 2013a) . The signature was defined by comparing the global transcription of pretreatment lesions from patients with metastatic melanoma who experienced clinical benefit with those from patients who did not. A classifier consisting of 84 genes discriminated the two groups and was also predictive of prolonged survival. This classifier was highly enriched in immune-related genes, which were coordinately overexpressed in lesions from responding patients. Impressively, these genes largely overlap with those observed in the ipilimumab trial (Ji et al., 2012) . Transcripts upregulated in responding lesions included genes coding for specific chemokines (CXCL2, CXCL9, CXCL10, and CCL5), cytotoxic granules (GZMK), HLA class I and II molecules, T cell-surface markers (CD3D, CD8A, and IL2RG), T cell-activation markers (ICOS and CD86), NK cell-associated genes (KLRD1 and KLRB1), and other classical IFN-stimulated genes (STAT1, IRF1, JAK2, PSMB9, GBP1, GBP5, and FAM26F (A) Postulated impact of cancer treatments on the tumor microenvironment. Therapies designed to target tumor cells can also induce changes in the immune response and tumor microenvironment. These responses are amplified in the setting of immunotherapies, which boost naturally occurring (but suppressed) antitumor immune response. In some patients this intratumoral immune response can slow down tumor growth or eventually mediate long-lasting tumor regression. Chemo, chemotherapy; Radio, radiotherapy; Small molec, small molecules (kinase inhibitors); Tumor-mAbs, tumor-directed antibodies; ImmunemAbs, immune-directed antibodies (checkpoint blockade inhibitors); TLR, toll-like receptor agonists; CYT, cytokines (i.e., IL-2); VAC, vaccines; ACT, adoptive cell-transfer therapy. (B) Proposed quantitative continuum between prognostic, predictive and mechanistic signatures. It could be hypothesized that the lowest level of immune activation is a feature of predictive signatures that cannot affect tumor growth (or risk of recurrence when the primary tumor is excised) in natural conditions. It is followed by prognostic signatures of insufficient intensity to cause cancer eradication but capable of controlling tumor growth (or tumor recurrence). The maximal intensity of immune response (captured by mechanistic signatures) occurs in lesions that are about to regress after immunotherapy administration. (C) Potential qualitative difference in overlap between immune and nonimmune prognostic, predictive, and mechanistic signatures. Only immune signatures measure the status of activation of a naturally protective mechanism, which, if successfully elicited, can lead to tumor regression. For this reason it is probable that predictive immune signatures will overlap (qualitatively) with the prognostic and the mechanistic ones. This is not the case, however, of nonimmune-related signatures, which, in general, measure cancer cell centric characteristics. and its predictive role was further confirmed in a second study assessing the efficacy of postoperative MAGE-A3 administration in patients with stage I-IIB non-small cell lung cancer (NSCLC). The presence of this similarity among different cancer pathologies supports a classification of cancer immune responsiveness independently of their tissue origin. Nevertheless, the MAGE-A3 gene signature did not predict relapse or survival in patients with NSCLC treated with placebo, suggesting that, in this setting, it bears a strictly predictive role. The study was, however, grossly underpowered in the detection of differences in subgroup analyses stratified according to histotype or clinical stage.
An increasing number of observations suggest that the presence of T cell immune infiltrates could favorably influence treatment responsiveness to cytotoxic agents. In hepatic metastases of CRC, high densities of CD3 + , CD8 + , and Granzyme B + cells at the IM were predictive of prolonged relapse-free survival in patients treated with conventional chemotherapy +/À cetuximab or bevacizumab antibody therapy (Halama et al., 2011) . The survival benefit of 5-fluorouracil-based chemotherapy in CRC patients was greatly improved by the presence of tumor-infiltrating lymphocytes (Morris et al., 2008) . By analyzing samples from patients enrolled in a large phase III trial, Loi et al. (2013) showed that, in HER2-positive early-stage breast cancer, the presence of lymphocyte infiltration predicts the response to non-antracycline-based adjuvant chemotherapy. Moreover, the presence of intratumoral lymphocytes, associated with the upregulation of the T cell-related transcripts CD3D and CXCL9, was a significant independent predictor of pathologic complete response in patients with breast cancer treated with neoadjuvant chemotherapy (Denkert et al., 2010) . In the same settings, a meta-analysis of eight microarray data sets (Ignatiadis et al., 2012) showed that two (previously published) immune-signatures genes (Desmedt et al., 2008; Teschendorff et al., 2007) , of which one centered on STAT1-IFN-stimulated genes, were associated with complete remission after neoadjuvant chemotherapy (Ignatiadis et al., 2012) . Interestingly, the strongest association was found in HER2-positive tumors, wherein the predictive value was superior to those of 15 other published nonimmunologic signatures (Ignatiadis et al., 2012) . Whether this phenomenon is due to the ability of an immunologically active microenvironment to enhance the cytotoxic activity of chemotherapeutic agents is still unknown. Alternatively, the cancer cell death induced by chemotherapy may act as an ''immune adjuvant'' by increasing the release of tumor-associated antigens (Lake and van der Most, 2006) , with consequent induction of a more potent acute immune-mediated response in those tumors bearing a subacute inflammatory phenotype.
Mechanistic Immune Signatures Associated with Effective Immune Rejection in Distinct Types of Cancer
Determining the mechanisms associated with treatment success (or failure) at the time when tumor rejection is occurring is critical because it highlights the ultimate biological objective of interventions aimed at inducing immune-mediated tumor regression. Few studies have addressed this issue, however. This lack of information is largely due to the intrinsic difficulty of studying the tumor microenvironment in vivo (Marincola, 2011) .
We define intratumoral mechanistic signatures as those that describe the effects of a given treatment, through direct observation of the target tissue (in this case the tumor) that allows discrimination of the effect of treatment based on the behavior of the studied lesion. The most accurate method for identifying mechanistic signatures is monitoring intratumoral processes by prospectively following, through noninvasive biopsies (e.g., fine-needle aspirate [FNA] ), the same lesion before and after treatment. In addition to the problem of safe and precise access to the visceral sites, the scarce amount of material available for analysis makes the evaluation of architectural changes of the immune contexture difficult to assess. To overcome these limitations, investigators have proposed to study the effect of therapeutic immune manipulation by tracking early treatmentinduced transcriptional changes in easily accessible tumor lesions (e.g., cutaneous and subcutaneous lesions) (Panelli et al., 2002 (Panelli et al., , 2007 Wang et al., 2002) . Using this approach, mechanistic signatures were investigated in patients affected by metastatic melanoma undergoing treatment with systemic IL-2 (Panelli et al., 2002; Wang et al., 2002; Weiss et al., 2011) and in patients with primary basal cell carcinoma treated with topic administration of a TLR7 agonist (imiquimod) (Panelli et al., 2007) . In a first study, FNA of cutaneous and subcutaneous melanoma lesions was collected before and 3 hr after the first and the fourth doses of IL-2 (Panelli et al., 2002) . Intrinsic characteristics of tumor lesions had a major impact on determining reactivity to IL-2 administration. In fact, posttreatment biopsies segregated according to sample origin independently of the time point. Surprisingly, no evidence of lymphocyte migration at the tumor site was observed at this early time point, as demonstrated by the lack of overexpression of genes codifying for proteins constitutively expressed by immune cells (i.e., CD3, CD4, CD8, CD10, TCR, CD20, CD11, CD14, CD16 FC-g, and CD83). Although microarray analysis of tumor biopsies does not allow discernment of the individual contribution of different cell types, the transcriptional changes induced by IL-2 administration could be best explained by activation of macrophage and monocyte functions in the absence of T cell migration. These transcripts codify for IFN-stimulated genes preferentially induced by the IFN-g-STAT1-IRF1 pathway and include GBP1, HLA class II molecules, and CXCR3 ligand genes (i.e., CXCL9 and CXCL10). Another subset of proinflammatory chemokine genes, including the CCR2 ligands CCL2 and CCL7 and the CCR5 ligands CCL3 and CCL4, was also overexpressed in posttreatment lesions. Such chemokines mediate chemotaxis of monocytes, NK cells, and activated cytotoxic and Th1 cells (Franciszkiewicz et al., 2012) . Overall, this transcriptional program seems indicative of macrophage activation, probably shifted toward an M1 lineage, which is thought to exert a powerful antitumor inflammatory function through the induction of a polarized Th1 cell inflammation (Mantovani et al., 2008) . Other genes specifically activated in posttreatment tumor metastases included cytokine receptors (e.g., IL2RB and IFNGR1), adhesion molecules associated with mononuclear cell migration (e.g., SELP and VCAM1), and genes associated with cytotoxic mechanisms in monocytes, NK cells, and activated T cells (e.g., GCA and GNLY). In a subsequent placebo-controlled, randomized trial, a similar approach was employed to assess the molecular variations induced in basal cell-carcinoma lesions by the topical administration of imiquimod (Panelli et al., 2007) . Analysis of paired punch biopsies pre-and posttreatment revealed that the inflammation induced by imiquimod was sustained by the activation of the same molecular pathways modulated by IL-2. However, imiquimod administration led to a more pronounced activation of the immune effector function genes (e.g., GNLY, PRF, and genes encoding the different granzymes), accompanied by the induction of proapoptotic caspase genes (CSPs). The concomitant overexpression of markers of immune infiltration (CD4, CD8, and CD56) strongly suggested that these proapoptotic events are engaged by the coordinated activation of cytotoxic cells eventually recruited through the aforementioned chemokine pathways. The higher activation of immune-effector genes induced by imiquimod is in line with the relatively higher clinical activity of this agent (approximately 80%-90% of complete remission rate). Interestingly, the upregulation of specific inflammatory pathways was maximal in the arm treated with a highly effective dose-intense schedule, indirectly underlying a relationship between the degree of the inflammation and the achievement of a clinical response. Another study, directed at patients with metastatic melanoma treated with IL-2 and various vaccination schedules, corroborated this hypothesis . When the analysis of treatment-induced transcriptional changes was stratified according to clinical response, it was evident that the nonresponsive tumors displayed an indolent and unreactive immune microenvironment. Conversely, sensitive tumors, which subsequently underwent complete remission, promptly reacted to immune stimulation by shifting toward an acute inflammatory status through the activation of the key transcription factor, IRF1. Weiss et al. (2011) profiled FNA samples from a small but homogenous cohort of patients with melanoma pre-and posttreatment with IL-2. The results confirmed that IL-2 induces activation of molecular pathways associated with monocyte activation, including the CCR5 signaling pathway. Comparison among posttreatment lesions showed that the majority of pathways upregulated in responding lesions were associated with effector immune responses. These signatures included a broad upregulation of HLA class II molecules, which are regulated by IFN-g-IRF-1 signaling. As mentioned above, such transcriptional differences were already observed when the same analysis was carried out in pretreatment lesions, providing evidence that they represent a magnification of a pre-existing phenomenon. Similar conclusions were reached by Ji et al. (2012) , who profiled prospectively excised melanoma metastases before and 3 weeks after the first ipilimumab administration. IFNG, CD8B, major histocompatibility complex class II genes, CCL4, CCL5, CXCL9, CXCL11, NKG7, GZMs, and PRF1 were all upregulated in post-compared to pretreatment samples, and this enhancement was greater in patients who subsequently experienced clinical benefit. Transcriptional analysis of several melanoma metastases obtained from two patients experiencing a mixed response to treatment corroborated these findings (Carretero et al., 2012) The analysis of divergent behavior of tumor lesions belonging to the same patient and treated simultaneously excludes from the tumor-host algorithm modulatory variables related to the hosts' genetic background and/or to environmental factors. Comparisons between multiple regressing and progressing melanoma metastases obtained from two patients treated with either autologous vaccination (M-VAX) or IFN-a revealed that genes differentially expressed by regressing versus progressing lesions were associated with acute immune response. Induction of the IRF-1-STAT-1 pathway was observed only in regressing lesions and associated with the activation of chemokines (CCL3 and CCL4) and genes associated with T and NK cell infiltration and cytotoxic functions. Given that these lesions were excised weeks or months after treatment administration, these data (combined with the above-described observations) suggest that the migration of immune cells at the tumor site is a relatively late, yet necessary, event. The similarity between mechanistic signatures associated with tumor rejection among distinct immunotherapeutic approaches provides evidence that tissue destruction triggered by different immune-therapy approaches converges, when effective, into a single molecular mechanism.
Analogies between Mechanistic Immune Signatures Associated with Cancer Rejection and Other Types of Immune Rejection
In 1969, Jonas Salk proposed that chronic infections, allograft rejections, autoimmune disorders, and cancers belong to a common phenomenon that he named the ''delayed allergy reaction'' (Salk, 1969) . The existence of a paradoxical continuum among different yet intriguingly similar immune-mediated conditions described in the previous paragraphs seems pertinent to Salk's hypothesis. In the last decade, several observational studies have molecularly characterized the mechanism underlying the phenomenon of immune-mediated tissue-specific destruction and its convergence into the activation of a limited number of pathways included in the ICR (Wang et al., 2008) .
Although it is clear that the primum movens leading to tissue destruction differ among immune-meditated diseases, the overwhelming analogies among molecular mechanisms activated in tissue experiencing rejection suggest that the immune-mediated tissue-destruction processes eventually converge into a common final pathway. This includes the coordinated activation of IFN-stimulated genes toward a Th1 cell polarization, the recruitment of cytotoxic cells through the production of specific chemokine ligands, and the activation of immune-effector function genes. We defined these common themes as follows: (1) the IFN-g-STAT1-IRF1-IFN-stimulated gene pathway; (2) the specific chemokine ligand pathway (CXCR3 and CCR5 ligand pathway); and (3) the immune-effector function pathway (for example, GZMs, PFR, GNLY, and CSPs). The themes pertain not only to tumor rejection but also to most facets of immunemediated tissue-specific destruction.
Seventy years ago, Peter Medawar demonstrated that allograft rejection is an immune-mediated phenomenon. In the mid 1950s, this phenomenon was shown to be similar to the process that confers immunity to tuberculosis, also called cell-mediated delayed hypersensitivity (Medawar, 1944) . At the time, Peter Gorer also advocated the role of humoral immunity in the development of acute allograft rejection (Gorer, 1942) . It is now clear that both humoral and cellular immunity are involved in the pathogenesis of allograft rejection and that the international pathologic classification divides allograft rejection into T cell-mediated and antibody-mediated rejection. However, by profiling a large cohort of kidney biopsies with histopathological diagnosis of acute allograft rejection, Mueller et al. (2007) showed that a specific inflammation score, based on a modular analysis of the gene-expression profile, correlated quantitatively with lesion phenotypes defined according to standard histopathological criteria. Although biopsies with the diagnosis of acute allograft rejection had elevated scores, they displayed a similar geneexpression pattern, irrespectively of the cellular or antibodymediated nature of rejection. This signature demonstrates cytotoxic T cell infiltration, upregulation of IFN-g transcripts, and activation of immune-effector genes such PRF1 and GZMs. In a meta-analysis of four independent kidney-transplant microarray databases, Saint-Mezard et al. (2009) found that the most consistently upregulated genes in acute allograft rejection were associated with antigen-presenting cells, CCR5 and CXCR3 ligand pathways, IFN response, and immune-effector functions. Recently, a comparative meta-analysis of 15 microarray studies in kidney, heart, lung, and liver recipients confirmed that these pathways are consistently activated during acute allograft rejection. IRF1 and STAT1 were predicted to be the key regulators of the majority of the upregulated genes extracted from microarray data sets . Similarly, in GVHD, the infiltration of CD45RO + effector memory T cells, expressing CXCR3 and markers of cytotoxicity, were associated with the induction of IFN-stimulated genes and apoptotic mechanisms and correlated with the presence and severity of the disease (Imanguli et al., 2009) .
In several autoimmune diseases, including lupus erythematous, rheumatoid arthritis, multiple sclerosis, Crohn's disease, autoimmune thyroiditis, and hepatitis, the importance of the recruitment of activated T cells through the activation of the CXCR3 and/or CCR5 pathway has been well established (Ajuebor et al., 2006; Godessart and Kunkel, 2001; Rotondi and Chiovato, 2011) . It is also observed in other inflammatory conditions such as chronic bronchitis (Costa et al., 2008) , cardiovascular disease (Okamoto et al., 2008) , and placental villitis (Kim et al., 2009) . By performing global gene-expression analysis of synovial-lining regions by microarray, Yoshida et al. (2012) showed that the expression levels of STAT1, IRF1, and specific chemokines (CXCL9, CXCL10, and CCL5) were dramatically increased in patients with rheumatoid arthritis compared with controls (patients with osteoarthritis). In the liver of patients chronically infected with hepatisis C virus, the overexpression of CXCR3 ligands correlates with the grade of necroinflammation and fibrosis (Zeremski et al., 2008) . However, after IFN-a administration, the intrahepatic activation of IFN-stimulated genes (Feld et al., 2007) associated with the induction of STAT1 phosphorylation (Sarasin-Filipowicz et al., 2008 ) and a sharp increase in the serum level of CXCL9 and CXCL10 (Florholmen et al., 2011) correlates with a sustained virologic response, resembling patterns observed in cancer immunotherapy. These data illustrate the analogies between mechanistic signatures across immune-mediated tissue destruction, including tumor rejection.
The Molecular Continuum between Prognostic, Predictive, and Mechanistic Immune Signatures As discussed in the previous paragraphs, prognostic, predictive, and mechanistic immune signatures are largely overlapping, and yet they are seen to be associated with remarkably different phenomena. In the case of prognostic and predictive signatures, their presence is not necessarily associated with evidence of tumor regression. Rather, they may underlie a subtle process, wherein the rate of tumor growth is slowed (prognostic signatures) or perhaps not affected at all (predictive signatures) unless an intervention is applied to amplify their power through immune manipulation of the host. On the contrary, mechanistic signatures are observed during the active phase of tumor destruction, and parallel signatures are observed in other immune events wherein tissue-specific destruction occurs, such as allograft rejection Wang et al., 2008) . The most logical explanation for this paradoxical observation is that although qualitatively redundant, these signatures may differ quantitatively in the number of transcripts affected and the intensity of their activation. This explanation currently remains a conjecture, because very little has been done to compare the intensity of the responses within the context of the same disease and treatment. Most studies performed thus far compare tissues transversally across patients rather than longitudinally. Only a few studies have reported comparisons between predictive and mechanistic signatures by assessing pretreatment and post/during-treatment events. A comparison of pre-versus posttreatment FNA melanoma lesions demonstrated qualitatively similar but quantitatively enhanced transcriptional patterns in patients who underwent treatment with IL-2 and experienced tumor regression (Weiss et al., 2011) . Similar observations were made by Ji et al. (2012) in the ipilimumab trials. Thus, the presence of immune cells and their functional orientation may reflect a distinct underlying biology of tumors that may affect their natural history (prognostic signatures) or their likelihood of responding to immune-stimulatory therapies (predictive signatures), or may directly induce tumor rejection following a continuum crescendo of intensity (mechanistic signatures) ( Figure 3B ). It could be hypothesized that the lowest level of activation characterizes predictive signatures that cannot affect tumor growth in natural conditions, followed by prognostic signatures of insufficient intensity to cause complete eradication but capable of controlling tumor growth. It is also possible that in certain conditions, depending on the stage or (possibly) on the cancer histotype (e.g., NSCLC, Ulloa-Montoya et al., 2013), the relatively low degree of immune activation may be completely inadequate to slow down the progression or to counteract the spread of cancer as it becomes insensitive to immune surveillance during the process of immunoescape (Wang et al., 2013a) . This hypothesis might conciliate the apparently clashing observations that the predictive MAGE-A3 immune signature did not bear prognostic significance in stage I-IIB NSCLC (Ulloa- Montoya et al., 2013) , whereas the expression of CCL5 was associated with favorable prognosis in stage I NSCLC adenocarcinoma (Moran et al., 2002) .
Interestingly, it was reported that the majority of patients with a strong, coordinated cytotoxic intratumoral T cell infiltration (high Immunoscore) presented at the time of diagnosis with early-stage CRC, whereas patients with a low cytotoxic response evolved to late-stage disease (Mlecnik et al., 2011b) . This may argue for a local control of primary tumor growth by cytotoxic T cells. Furthermore, the T stage and N stage were no longer significant in Cox multivariate analysis together with the Immunoscore, supporting the significant statistical dependency of tumor progression and invasion with the intratumor immune cell densities and the dominant importance of immune cell infiltration on the long-term survival of patients (Mlecnik et al., 2011b) (Figure 3B ). It should be emphasized that the incremental scale of activation conjectured to explain the progression from predictive to mechanistic signatures is only conceptual and should probably be adjusted to the sensitivity of tumor cells to immune destruction. In other words, the balance between the strength of the immune response and the mechanisms adopted by tumors to escape immune recognition, rather than the absolute level of activation, is more likely to determine the overall results.
Intratumoral immune biomarkers measure the status of activation of a naturally protective mechanism, which, if successfully elicited, will lead to tumor destruction. Thus, with a few exceptions, it is probable that predictive immune biomarkers will overlap with the prognostic and the mechanistic ones. This is not the case, however, for nonimmune-related markers, in which prognostic, predictive, and mechanistic ones only minimally overlap ( Figure 3C ). In fact, nonimmune biomarkers measure intrinsic characteristics linked with tumor cell biology. However, conventional therapy (chemotherapy, tumor-centered target therapy, and radiotherapy) aims in general at repressing (directly or indirectly) the process identified by such biomarkers, making the overlap between the prognostic, predictive, and mechanistic a rare event. Although the redundancy between prognostic, predictive, and mechanistic immune signatures could seem obvious, the basis of its molecular continuum, to the best of our knowledge, has been never formalized before. We hope to have provided here sufficient and convincing arguments to support this emerging concept.
The Proposed Origins of Immune Signatures
It remains largely unclear why some tumors display an inflammatory-favorable status and others do not. The complex and dynamic interaction between cancer cells, stromal cells, and immune cells makes it difficult to dissect the distinct contribution of the different cell subtypes in determining the desirable phenotype. Gene-expression profiling of the whole tumor allows the determination of the final molecular vector. According to a perhaps overly simplistic interpretation, it is generally assumed that the immune signature detected by profiling tumor biopsies is mainly the result of the presence and/or the activation of immune cells. However, several observations suggest that this immune signature can also reflect features of cancer cells. By selectively profiling serous-tumor epithelium isolated by laser microdissection, Callahan et al. (2008) showed that expression of HLA class II molecules, as well as the expression of IRF1 by tumor cells, correlated with the presence of CD8 + T cells. Similarly, Zeimet et al. (2009) found that IRF1 expression in ovarian cancer correlates with the presence of CD3 + T cells. However, only ovarian cancer cells invariably stained positively for IRF1, which was expressed by a small fraction of lymphocytes and not expressed at all by stromal cells. These studies suggest that tumor cell signals contribute to the immune signature. Moreover, they cannot substantiate that the activation of HLA or IRF1 drives the CD8 + response rather than representing the consequence of the release of IFN-g or other immune stimulants by cytotoxic T cells. Gene signatures implying constitutive activation of innate mechanisms including IFN-stimulated genes in cancer cells have been described (Monsurrò et al., 2010) . The overexpression of IRF1 (Zeimet et al., 2009 ) or a constitutional, yet mild, activation of pSTAT-1 (Lesinski et al., 2007) has been observed in a significant proportion of resting human cell lines, suggesting that intrinsic cancer biology can potentially contribute, at least in part, to the genesis of the immune signature. Concordantly, constitutive activation of the JAK1-STAT1 pathway in a relatively high percentage of melanoma cells expanded in unconditioned culture medium (De Giorgi et al., 2012, Soc. for Immunotherapy of Cancer, abstract). By analyzing sample biopsies from melanoma metastatic patients through gene-and protein-expression arrays, Harlin et al. (2009) observed that a subset of six chemokines (CCL2, CCL3, CCL4, CCL5, CXCL9, and CXCL10) strongly correlated with the presence of T lymphocytes. By using the supernatant of melanoma cell lines (secreting all the aforementioned chemokines), the authors proved their ability to recruit CD8 + effector T cells in vitro. However, it should be taken into account that several cell types, including activated T cells, DCs, macrophages, endothelial cells, epithelial cells, and stromal cells, can secrete these chemokines (Balkwill, 2012; Castiello et al., 2011; Franciszkiewicz et al., 2012) . Recently, Spivey et al. (2012) defined three different molecular subtypes of melanoma metastases based on the top genes concordantly expressed by them and their derived cell lines and also showing transcriptional efficiency according to copy-number variation analysis. One class of melanoma metastases, enriched in Th1 genes (e.g., GBP1, STAT1, and CXCL10), was also enriched in several genes associated with melanoma-specific processes along the MAP kinase pathways, in agreement with those observed in breast cancer (Ignatiadis et al., 2012) . However, there was a lack of correlation in the expression of the aforementioned chemokines and Th1 genes among melanoma cell lines and their parental metastases, suggesting that the determination of this inflammatory phenotype does not represent a linear transposition of the cancer genetics (Bedognetti et al., 2012, ASCO, abstract) . Rather, it reflects a complex, multifactorial, in vivo phenomenon probably resulting from the interactions (and interdependency) between the genetics of the host and of the 
Immunity
Review tumor, along with other hidden variables (e.g., environmental factors) (Figure 4 ).
Future Perspective
As described above, gene-expression profiling and computerassisted immunohistochemistry have provided novel insights into mechanisms regulating the antitumor response. Future investigations involving integration of high-throughput approaches should better define the dependency on the genetic makeup of the individuals bearing the disease, on the somatic mutations within cancer cells, or on other influencing elements (Ogino et al., 2011; Uccellini et al., 2012; Wang et al., 2012; Zitvogel et al., 2012) . Emerging factors related to the host, including lifelong environmental exposure to aspects such as the microbiome, may alter immune responsiveness and should be considered (Grivennikov et al., 2012) . Multiple aspects could therefore act as a modifier, contributing to the natural or treatment-induced history of cancer. Thus, it will be important to perform simultaneous, integrated analysis to assess the dynamic behavior of human cancer, encompassing inborn genetic traits, somatic genetic and epigenetic alterations, and environmental contributions Wang et al., 2013b) .
Novel sophisticated technologies are constantly emerging. Collaborative projects, such as The Cancer Genome Atlas (TCGA), make use of integrated platforms including exon sequencing, genome-wide DNA methylation profiling, copynumber analysis, SNP profiling, and microRNA profiling. These strategies are utilized to explore the genomic landscape of cancer through a multidimensional approach and to define the genetic basis of its heterogeneity. TCGA data have recently been published for leukemia (Cancer Genome Atlas Research Network, 2013) , glioblastoma (Cancer Genome Atlas Research Network, 2008) , colorectal (Cancer Genome Atlas Network, 2012b), breast (Cancer Genome Atlas Network, 2012c; Verhaak et al., 2013) , ovarian (Cancer Genome Atlas Research Network, 2011), endometrial (Kandoth et al., 2013) , and squamous cell lung (Cancer Genome Atlas Research Network, 2012a) cancers. These approaches have already facilitated detection of novel somatic mutations (e.g., the HLA-A gene in squamous lung cancers) and have better defined molecular alterations yielding different tumor phenotypes. The TCGA breast cancer study confirmed that the classification, based on intrinsic geneexpression phenotypes, highly correlates with distinct DNA methylation, microRNA, copy-number aberration, and protein patterns, suggesting that heterogeneity occurs within, rather than across, these main phenotypes. Because TCGA data are publicly accessible, exploring the TCGA databases focusing on immune-regulation pathways could provide novel insights into the relationship between oncogenic processes and the immune system. In colorectal cancers, similar integromics analysis has shown that inflammatory pathways are deregulated in nonhypermutated versus hypermutated samples, which were enriched in tumors bearing high microsatellite instability. These findings support the correlation between microsatellite instability, density of T cell infiltration, and favorable prognosis, described by several authors (Guidoboni et al., 2001; Nosho et al., 2010) . For ovarian cancer, a subcluster of ''immunoreactive'' tumors, characterized by overexpression of CXCR3, CXCL10, and CXCL11 (Cancer Genome Atlas Research Network, 2011), was associated with 3q26.2 (MECOM) amplification. More recently this ''immunoreactive'' classification was associated with greater OS in TCGA and in two independent databases (Verhaak et al., 2013) . The availability of germline DNA sequences could thus facilitate exploration into the relationship between the genetics of the host and the development of a favorable immune phenotype. Li et al., for example, combined genome-wide association studies (GWASs) and TCGA approaches to ascertain the contributions of germline (GWAS) versus somatic (TCGA) variants in the oncogenic gene-expression pattern in breast cancer (Kim et al., 2013; Li et al., 2013) . The complexity and multidimensionality of orthogonal data sets make the development of novel multifactorial bioinformatics approaches an urgent requirement.
Beyond correlative studies, more mechanistic insights, aimed at explaining the sources of the molecular immunosignatures, are warranted. Functional characterization at the cell-specific level requires the use of deconvolution algorithms. Deconvolution algorithms (Shen-Orr et al., 2010) could increase sensitivity in detecting differentially expressed genes if the proportion of different cell populations is available (Shen-Orr et al., 2010) by solving linear-regression problems in which the cell-typespecific gene expression values represent the regression coefficients (Zhao and Simon, 2010) . If the proportion of the cell-type population is not available, deconvolution can still be performed if the expression of gene signatures in pure cell types is well characterized (Abbas et al., 2009 ). However, deconvolution might be prone to bias when applied to extremely heterogeneous and dynamic systems wherein the gene-expression profile of pure samples cannot be considered an accurate parameter of normalization. This is the case for tumor biopsies, wherein the gene-expression profiles in predefined cell subsets can change dramatically, influenced by cytokines, chemokines, and additional neighboring cells within the tumor microenvironment. Other approaches, such as flow cytometry and immunohistochemistry, are recommended for validating a deep characterization of the cellular component of a tumor biopsy. Little is known, for example, about the molecular features of other components of the tumor microenvironment in dynamic conditions. In particular, plasticity and the modulatory role of stromal cells are becoming increasingly understood (Finak et al., 2008) , and it is probable that they also contribute to the development of the inflammatory phenotype (Muthuswamy et al., 2012; Jin et al., 2012, Soc. for Immunotherapy of Cancer, abstract). Additionally, wide patient-to-patient variability is observed among tumor cell profiles, given that specific tumor cell signatures are largely modulable following different stimuli (Murtas et al., 2013) . Other approaches could consist of singlecell profiling following cell sorting or laser microdissection. These procedures also face limitations because they could modify cell physiology and induce a change in the gene and/or protein expression profile, but they are indeed promising. Generating tumor cell lines and matching their genomic and proteomic profile with the in vivo immune contexture of their parental metastases could help evaluate immune-activation characteristics of tumor cells. Many of these approaches have technical or practical restraints; therefore, a combination of techniques is likely to represent the best strategy. Regardless of the approach, adequate collection of clinical sample, especially within clinical trials, remains paramount.
Given the central role played by the activation of ICR pathways in inducing immune-mediated tissue destruction, we believe that strategies aimed at targeting the tumor microenvironment through enhancement could dramatically impact therapeutic outcomes in the near future. Combination therapies represent an intriguing and emerging approach Melero et al., 2013) . As described in this review, immunotherapeutic approaches share similar mechanisms of actions and, therefore, are likely to interact in a synergistic fashion. Strikingly, in patients with metastatic melanoma, the addition of IL-2 to ipilimumab strongly enhances its efficacy (Prieto et al., 2012) . Similar combinations could be explored by combining other drugs targeting immune-checkpoints such as anti-PD-1 and anti-PD-L1 (B7-H1) (Melero et al., 2013) . Interestingly, Muthuswamy et al. (2012) have recently reported that a combination of IFN-a with a TLR3 agonist can dramatically and uniformly enhance the production of CXCL10 and CCL5 in human colon tumor explants. Such a chemokine-modulatory regimen (with the addition of a COX1 inhibitor to suppress the regulatory CCL22 chemokine) is currently being tested in phase I/II trials. In addition, once somatic mutations and epigenetic characteristics of tumor cells have been linked with immunosuppressive characteristics, targeting the driver oncogene would represent an indirect way to revert the immunosuppressive phenotype, therefore facilitating the effectiveness of immunotherapy (Ribas and Wolchok, 2013) .
Pathological evaluation of the immune contexture using the Immunoscore as part of the routine diagnostic and prognostic assessment of tumors may provide crucial novel prognostic information, facilitate clinical decision-making, including rational stratification of patient treatment, and guide therapeutic strategies Pagè s et al., 2010) . Our groups, together with the Society for Immunotherapy of Cancer, initiated an international task force to promote the use of the Immunoscore in routine clinical practice . It is now recognized that the clinical outcome can vary significantly among patients within the same cancer stage. The current AJCC/UICC TNM classification provides limited prognostic information and does not predict response to therapy. Accumulating data from large cohorts of human cancers has demonstrated the impact of immune classification, which has a prognostic value that may add to the significance of the current classification and that has been demonstrated to be superior to the AJCC/UICC TNM classification in CRC. It is therefore imperative to begin to incorporate a standard test such as the Immunoscore into the current classification, thus providing an essential prognostic and potentially predictive tool. Given the power of intratumor immune quantification, the Immunoscore is likely to be important for the field of cancer beyond the field of tumor immunology. Thus, the results of this international Immunoscore task force may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune) .
A similar initiative could be applied for the validation of immune gene signatures. The use of immune signatures could be particularly useful in the case of metastatic patients when the evaluation of the Immunoscore is unfeasible due to limited starting material (collected in general through FNA or punch biopsies). As for immunotherapy, the MAGA-A3 gene signature (Ulloa-Montoya et al., 2013) , which largely overlaps with the ipilimumab gene signature (Ji et al., 2012) , encapsulating the ICR pathways, is in an advanced phase of validation in two MAGE-A3 phase III trials directed at patients with lung cancer and metastatic melanoma.
We believe that the evaluation of these immune gene signatures should be prospectively evaluated in early immunotherapy trials assessing novel agents or agent combinations. So far, no biomarkers allowing patient selection are available in the field. Given that immunotherapy trials also compete with biological target therapies, the availability of a validated gene signature allowing the identification of patients more likely to respond to immune manipulation would dramatically improve patient stratification in early clinical-trial development.
